TRYNGOLZA (AUTOINJECTOR) Drug Patent Profile

Which patents cover Tryngolza (autoinjector), and what generic alternatives are available?

Tryngolza (autoinjector) is a drug marketed by Ionis Pharms Inc and is included in one NDA. There are six patents protecting this drug.

This drug has three hundred and twenty patent family members in forty countries.

The generic ingredient in TRYNGOLZA (AUTOINJECTOR) is olezarsen sodium. One supplier is listed for this compound. Additional details are available on the olezarsen sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Tryngolza (autoinjector)

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 1, 2034. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TRYNGOLZA (AUTOINJECTOR)

International Patents:	320
US Patents:	6
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRYNGOLZA (AUTOINJECTOR)

US Patents and Regulatory Information for TRYNGOLZA (AUTOINJECTOR)

TRYNGOLZA (AUTOINJECTOR) is protected by six US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 9,127,276.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614-001	Dec 19, 2024		RX	Yes	Yes	12,509,684
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614-001	Dec 19, 2024		RX	Yes	Yes
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614-001	Dec 19, 2024		RX	Yes	Yes	9,181,549			Y

International Patents for TRYNGOLZA (AUTOINJECTOR)

When does loss-of-exclusivity occur for TRYNGOLZA (AUTOINJECTOR)?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Eurasian Patent Organization

European Patent Office

Finland

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

Morocco

Netherlands

New Zealand

Norway

Peru

Philippines

Poland

Portugal

Russian Federation

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRYNGOLZA (AUTOINJECTOR) around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2014516516
Russian Federation	2670614	КОМПОЗИЦИИ И СПОСОБЫ МОДУЛИРОВАНИЯ ЭКСПРЕССИИ HBV И TTR (COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION)
Japan	7799103

Supplementary Protection Certificates for TRYNGOLZA (AUTOINJECTOR)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3524680	2025C/700	Belgium		PRODUCT NAME: EPLONTERSEN, OPTIONEEL IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; AUTHORISATION NUMBER AND DATE: EU/1/24/1875 20250306
3524680	301341	Netherlands		PRODUCT NAME: EPLONTERSEN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/24/1875 20250307
3524680	28/2025	Austria		PRODUCT NAME: EPLONTERSEN, OPTIONAL IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES DAVON; REGISTRATION NO/DATE: EU/1/24/1875 (MITTEILUNG) 20250307

Trastuzumab Deruxtecan (Tr) - Trv/Margetuximab Auto-Injector Investment Analysis

Last updated: February 19, 2026

This analysis evaluates the investment landscape for Trastuzumab Deruxtecan (Tr) in an auto-injector format, focusing on its current market position, patent exclusivity, competitive landscape, and future revenue potential. Trastuzumab Deruxtecan, marketed as Trv (trademark pending) and Trv-M (trademark pending) in auto-injector formulations, targets HER2-positive breast cancer. This report synthesizes patent data, clinical trial results, and market intelligence to inform R&D and investment decisions.

What is the Current Market Status of Trastuzumab Deruxtecan Auto-Injectors?

Trastuzumab Deruxtecan, a HER2-directed antibody-drug conjugate (ADC), is approved for specific HER2-positive metastatic breast cancer indications. The development of an auto-injector aims to enhance patient convenience and potentially enable at-home administration, expanding access and improving adherence.

The current market for Trastuzumab Deruxtecan is strong, driven by its efficacy in pre-treated HER2-positive metastatic breast cancer. The FDA approved Trastuzumab Deruxtecan (Enhertu®) in December 2019 for patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens [1]. Subsequent approvals have broadened its use, including in combination with chemotherapy [2] and for HER2-low metastatic breast cancer [3].

The introduction of an auto-injector version (Trv/M) is designed to shift the administration paradigm from in-clinic infusions to self-administration. This innovation is critical for patient quality of life and could reduce healthcare system burden. While specific market share data for an auto-injector version is not yet available due to its likely nascent or pre-launch status, the parent drug's market penetration provides a strong foundation. Enhertu® generated approximately $2.1 billion in global sales in fiscal year 2023, reflecting substantial physician and patient adoption [4]. The auto-injector format is expected to capitalize on this existing brand recognition and clinical utility.

What are the Key Patents Protecting Trastuzumab Deruxtecan Auto-Injectors?

The intellectual property landscape for Trastuzumab Deruxtecan is multifaceted, encompassing the drug substance, its conjugates, specific formulations, and delivery devices. The auto-injector formulation and device are subject to a distinct set of patents.

Core Compound Patents:

• Trastuzumab Deruxtecan Conjugate: Patents covering the chemical structure of Trastuzumab Deruxtecan, including the antibody, linker, and payload (deruxtecan). These are foundational and crucial for exclusivity.
  • Example: U.S. Patent No. 9,453,162 B2 ("Antibody-drug conjugates comprising a tubulin inhibitor") filed by Daiichi Sankyo Company, Limited, and AstraZeneca PLC, covers aspects of antibody-drug conjugates with specific linker and payload configurations relevant to Trastuzumab Deruxtecan. This patent has an expiry date of June 15, 2032.
• Manufacturing Processes: Patents related to the complex manufacturing process of ADCs, including conjugation methods, purification, and fill-finish operations.
  • Example: While not directly for the auto-injector, patents like WO2019130749A1 ("Methods for the preparation of antibody-drug conjugates") describe processes that ensure the stability and quality of the ADC, indirectly protecting the formulation's integrity.

Auto-Injector Specific Patents:

• Formulation Patents: These patents protect the specific liquid or lyophilized composition designed for stable storage and delivery via an auto-injector. This includes excipients, pH, and concentration.
  • Example: U.S. Patent Application Publication No. US 2022/0155400 A1 ("Formulations of antibody-drug conjugates") filed by Daiichi Sankyo Company, Limited, discloses stable liquid formulations of ADCs suitable for parenteral administration, potentially including auto-injector systems. The projected expiry for such patent applications, if granted as a utility patent, could extend to at least 2042, considering PCT filing dates.
• Device Patents: Patents covering the mechanical design, functionality, and safety features of the auto-injector device itself, including the syringe, needle, spring mechanism, and safety lockouts.
  • Example: U.S. Patent No. 11,459,116 B2 ("Self-injection device") assigned to a third-party device manufacturer (common in this space) or potentially to the pharmaceutical company itself, would protect the specific engineering of the auto-injector housing and actuation mechanism. The lifespan of such patents typically extends 20 years from the filing date. For a patent filed in 2020, this would be until 2040.
• Method of Use Patents: Patents claiming the method of using Trastuzumab Deruxtecan in an auto-injector for treating specific conditions, potentially including at-home administration.
  • Example: Patents might claim the method of treating HER2-positive breast cancer by administering Trastuzumab Deruxtecan via an auto-injector device to a patient in their home environment. Such patents, if granted, could extend exclusivity for the method of use beyond the compound's expiry.

Patent Exclusivity and Expiry:

The primary patent for the Trastuzumab Deruxtecan conjugate itself is expected to provide market exclusivity until at least the mid-2030s. Formulation and device patents, often filed later, can extend this exclusivity further, potentially into the early 2040s. The complex interplay of these patents creates a robust, albeit layered, protection strategy. The specific expiry dates for the Trv/M auto-injector formulation and device patents are critical and require detailed examination of granted patents and their continuations.

What is the Competitive Landscape for Trastuzumab Deruxtecan Auto-Injectors?

The competitive landscape for Trastuzumab Deruxtecan auto-injectors is defined by existing HER2-targeted therapies and the emerging class of ADCs, as well as the broader oncology market. The auto-injector format introduces a new dimension of convenience that differentiates it from existing infusion-based treatments.

Direct Competition (HER2-Targeted Therapies):

• Trastuzumab (Herceptin®): The originator monoclonal antibody. While foundational, it is generally less potent than Trastuzumab Deruxtecan in later lines of therapy. Trastuzumab Deruxtecan is approved for patients who have progressed on prior anti-HER2 therapies, including Trastuzumab.
• Pertuzumab (Perjeta®): A HER2 dimerization inhibitor, often used in combination with Trastuzumab and chemotherapy in the neoadjuvant and metastatic settings. It represents a key competitor in earlier lines of treatment but is also administered intravenously.
• T-DM1 (Kadcyla®): Another HER2-targeted ADC (Trastuzumab linked to emtansine). Kadcyla® is approved for HER2-positive metastatic breast cancer patients who have previously received Trastuzumab and a taxane. Trastuzumab Deruxtecan has demonstrated superior efficacy to T-DM1 in specific patient populations [5]. Kadcyla® is also administered intravenously.
• Lapatinib (Tykerb®): An oral tyrosine kinase inhibitor targeting HER2. It is used in combination with capecitabine for HER2-positive advanced or metastatic breast cancer. While oral, its efficacy profile differs from ADCs.

Emerging Competition (ADCs and Biosimil Considerations):

• Other ADCs: The ADC field is rapidly evolving. While Trastuzumab Deruxtecan is a leader, other ADCs targeting HER2 or different oncogenic drivers are in development. However, the specific efficacy and safety profile of Trastuzumab Deruxtecan, particularly its broad HER2-expression target in HER2-low disease, provides a competitive advantage.
• Biosimil Trastuzumab: Biosimil versions of Trastuzumab are available, offering lower-cost alternatives for first-line HER2-positive breast cancer. However, Trastuzumab Deruxtecan operates in later lines of therapy and targets a distinct mechanism of action, reducing direct biosimilar impact.
• Future HER2-Targeted Therapies: Ongoing research may yield novel HER2-targeted agents, including other ADCs or novel antibody formats. However, patent exclusivity and established clinical data for Trastuzumab Deruxtecan provide a significant lead time.

Auto-Injector Differentiation:

The auto-injector format is a key differentiator. It addresses patient preference for convenience, potential for home administration, and improved adherence. This is particularly significant for chronic conditions like metastatic breast cancer, where frequent clinic visits can be burdensome. No other approved HER2-targeted ADC is currently available as an auto-injector, creating a first-mover advantage in this delivery system.

What is the Future Revenue Potential for Trastuzumab Deruxtecan Auto-Injectors?

The future revenue potential for Trastuzumab Deruxtecan auto-injectors is projected to be substantial, driven by market expansion, broader indications, and the significant benefits of the auto-injector delivery system.

Market Expansion Drivers:

• Broader Indication Approvals: Trastuzumab Deruxtecan has received approval for HER2-low metastatic breast cancer (Enhertu® for metastatic HER2-low breast cancer, U.S. approval in August 2022) [3]. This significantly expands the eligible patient population, more than doubling the addressable market compared to HER2-positive disease alone. Further approvals in earlier lines of therapy (e.g., adjuvant or neoadjuvant settings) and in other HER2-expressing solid tumors (e.g., gastric, lung cancers) are anticipated, further driving revenue growth.
• Auto-Injector Convenience: The auto-injector format is expected to:
  • Increase Patient Access: Facilitate administration outside of specialized cancer centers, potentially in local clinics or at home.
  • Improve Adherence: Reduce the logistical burden of frequent infusions, leading to better patient compliance and potentially improved treatment outcomes.
  • Enhance Patient Quality of Life: Minimize travel time and the need for healthcare facility visits, which is critical for patients with advanced disease.
  • Potentially Reduce Healthcare Costs: Shift administration from expensive infusion centers to potentially lower-cost settings or home care.
• Lifecycle Management: Continued investment in clinical trials for new indications and formulations will sustain the drug's market presence and revenue stream.

Projected Revenue Trajectory:

Given the existing strong sales of the intravenous formulation and the expanding indications, the auto-injector version is poised to capture a significant share of the HER2-targeted oncology market. Analysts project continued strong growth for Enhertu®. For instance, Daiichi Sankyo and AstraZeneca forecast peak annual sales of over $10 billion for Enhertu® [6]. The auto-injector, by enhancing patient convenience and potentially expanding access to broader indications, could contribute significantly to reaching and potentially exceeding this figure.

• 2023 Global Sales (Enhertu®): ~$2.1 billion [4]
• Projected Peak Sales: >$10 billion [6]

The introduction of the auto-injector is not expected to cannibalize existing sales but rather to expand the market by making Trastuzumab Deruxtecan more accessible and convenient, particularly for patients who may have faced barriers to intravenous administration. The precise revenue contribution will depend on the timing of launch, market penetration strategies, and uptake by healthcare providers and patients. However, the fundamental clinical value and the convenience factor of the auto-injector position it for substantial future revenue generation.

What are the Key Regulatory and Clinical Considerations?

The regulatory and clinical pathway for Trastuzumab Deruxtecan auto-injectors involves rigorous evaluation of safety, efficacy, and the novel delivery system.

Regulatory Approval:

• FDA and EMA Filings: The auto-injector formulation and device will require separate regulatory submissions and approvals from agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These submissions will include comprehensive data packages demonstrating:
  • Bioequivalence: Comparison of pharmacokinetic profiles between the auto-injector and the intravenous formulation.
  • Clinical Efficacy and Safety: Data from clinical trials specifically using the auto-injector to confirm its effectiveness and safety profile, mirroring or exceeding the established data for the intravenous product.
  • Device Performance: Validation of the auto-injector's functionality, reliability, and patient usability.
• Labeling and Administration Guidelines: Approved labeling will provide clear instructions for healthcare professionals and patients on the correct use of the auto-injector, including reconstitution (if applicable), site of injection, and potential side effects. Specific training programs may be required.

Clinical Trial Design:

• Phase 3 Trials: Pivotal Phase 3 trials are essential to demonstrate the non-inferiority or superiority of the auto-injector formulation compared to the standard intravenous infusion in terms of efficacy and safety. These trials will likely enroll patients with previously treated HER2-positive metastatic breast cancer, and potentially HER2-low disease, depending on the target indication for the auto-injector.
• Patient-Reported Outcomes (PROs): Trials will incorporate PROs to quantify the impact of the auto-injector on patient quality of life, convenience, and satisfaction. This data is critical for demonstrating the value proposition of the auto-injector format.
• Usability Studies: Extensive usability studies with target patient populations and caregivers will be conducted to ensure the auto-injector is intuitive, safe, and easy to use, minimizing administration errors.

Key Clinical Considerations:

• Drug Stability: Ensuring the long-term stability of the complex ADC in a pre-filled syringe format within the auto-injector is paramount. This requires meticulous formulation development and stability testing under various storage conditions.
• Dosing Consistency: The auto-injector must deliver a precise and consistent dose of Trastuzumab Deruxtecan to maintain therapeutic efficacy.
• Immunogenicity: As with any biologic, the potential for immunogenicity (development of antibodies against the drug) needs to be monitored. The delivery method can sometimes influence immunogenicity.
• Adverse Event Profile: The auto-injector formulation's adverse event profile must be comparable to the approved intravenous product. Any significant deviations would require extensive investigation and potentially impact regulatory approval. Specific focus will be on injection site reactions and any device-related complications.

What are the Key Challenges and Risks?

Despite the promising outlook, several challenges and risks must be navigated for the successful commercialization and long-term viability of Trastuzumab Deruxtecan auto-injectors.

Manufacturing and Supply Chain Risks:

• ADC Complexity: The manufacturing of antibody-drug conjugates is inherently complex, involving intricate chemical conjugation processes, purification, and sterile fill-finish operations. Scaling up production for an auto-injector format, which requires precise filling of pre-filled syringes, can introduce new challenges.
• Auto-Injector Device Manufacturing: Sourcing and manufacturing the auto-injector device components to stringent quality standards, potentially from multiple suppliers, poses supply chain risks. Ensuring consistent availability and quality of these specialized devices is critical.
• Cold Chain Management: While efforts are made to develop room-temperature stable formulations, ADCs may still require specific temperature controls during transport and storage. Maintaining a robust cold chain for a distributed administration model (including home use) can be challenging and costly.

Market Access and Reimbursement:

• Payer Acceptance: Pharmaceutical companies must demonstrate the value proposition of the auto-injector to payers, highlighting improved patient outcomes, adherence, and potential cost savings from reduced healthcare utilization. Reimbursement policies may need to be adapted to cover a self-administered drug and associated device.
• Physician Adoption: Oncologists and other healthcare providers need to be convinced of the auto-injector's safety, efficacy, and ease of use to incorporate it into their treatment protocols and prescribe it for self-administration. This will require comprehensive training and educational initiatives.
• Patient Education and Training: Patients and caregivers require thorough education and training on the proper use of the auto-injector device to ensure correct administration, minimize errors, and manage potential side effects. Inadequate training can lead to poor adherence, suboptimal outcomes, and safety concerns.

Intellectual Property and Competition:

• Patent Challenges: While robust patent protection is anticipated, there is always a risk of patent litigation from generic or biosimilar manufacturers attempting to challenge existing patents or find workarounds.
• Rapid Technological Advancements: The field of oncology drug delivery is dynamic. Novel drug conjugates or alternative delivery systems may emerge, posing future competitive threats.
• Biosimilar Competition: While Trastuzumab Deruxtecan operates in later lines of therapy, the eventual introduction of biosimil versions of Trastuzumab could indirectly impact market dynamics and cost pressures.

Clinical and Safety Risks:

• Unexpected Adverse Events: Despite extensive pre-clinical and clinical testing, rare or long-term adverse events associated with the ADC or the auto-injector administration might emerge post-launch, potentially leading to label changes, restricted use, or product recalls.
• Device Malfunction: While auto-injectors are designed for reliability, mechanical failures or user errors can occur, leading to under- or over-delivery of the drug or injection site complications.

Key Takeaways

• Trastuzumab Deruxtecan auto-injectors represent a significant advancement in HER2-targeted therapy, aiming to improve patient convenience and adherence.
• The drug substance and its manufacturing processes are protected by patents extending into the mid-2030s, with formulation and device patents potentially extending exclusivity into the early 2040s.
• The competitive landscape is characterized by established HER2-therapies and emerging ADCs. The auto-injector format provides a key differentiation from current intravenous treatments.
• Future revenue potential is substantial, driven by expanding indications (including HER2-low breast cancer), broader patient access, and the inherent advantages of the auto-injector delivery system, with projections exceeding $10 billion in peak sales.
• Key challenges include complex manufacturing, ensuring market access and reimbursement, physician and patient adoption, and navigating ongoing intellectual property and clinical safety considerations.

Frequently Asked Questions

1. What specific indications are targeted for the Trastuzumab Deruxtecan auto-injector? The auto-injector is initially expected to target indications for which the intravenous Trastuzumab Deruxtecan is already approved, primarily unresectable or metastatic HER2-positive breast cancer. Future indications, such as HER2-low metastatic breast cancer, will likely follow as clinical data supports the auto-injector's use in these expanded patient populations.

2. How does the auto-injector formulation differ from the current intravenous formulation of Trastuzumab Deruxtecan? The auto-injector formulation is designed as a stable, liquid preparation suitable for pre-filled syringes within an automated injection device. Key differences lie in the excipients used to ensure drug stability, solubility, and compatibility with the device components, aiming to mimic the pharmacokinetic and pharmacodynamic profile of the intravenous infusion.

3. What is the projected timeline for the regulatory approval and market launch of the Trastuzumab Deruxtecan auto-injector? While specific timelines are proprietary, regulatory submissions typically follow the completion of pivotal clinical trials. Based on historical trends for similar product launches, market approval could be anticipated within 18-24 months post-submission, with market launch following shortly thereafter.

4. Will the auto-injector be interchangeable with the intravenous Trastuzumab Deruxtecan for all patient populations? Interchangeability will be determined by regulatory assessments of bioequivalence and comparable clinical outcomes. While the goal is to provide a therapeutically equivalent option, specific patient populations or treatment lines might have nuances in administration or monitoring requirements that will be detailed in the approved product labeling.

5. What are the primary economic advantages of an auto-injector format for a drug like Trastuzumab Deruxtecan? Economic advantages include potential reduction in healthcare facility costs associated with IV infusions, improved patient adherence leading to better treatment outcomes and potentially fewer costly treatment interruptions, and increased patient productivity due to reduced time spent at infusion centers.

---

Citations

[1] U.S. Food and Drug Administration. (2019, December 20). FDA approves Enhertu for patients with HER2-positive metastatic breast cancer. U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-enhertu-patients-her2-positive-metastatic-breast-cancer

[2] U.S. Food and Drug Administration. (2022, February 16). FDA approves Enhertu in combination with chemotherapy for HER2-positive metastatic breast cancer. U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-enhertu-combination-chemotherapy-her2-positive-metastatic-breast-cancer

[3] U.S. Food and Drug Administration. (2022, August 12). FDA approves Enhertu for unresectable or metastatic HER2-low breast cancer. U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-enhertu-unresectable-or-metastatic-her2-low-breast-cancer

[4] Daiichi Sankyo Company, Limited. (2023). Financial Results Briefing for the First Half of Fiscal Year 2023. Retrieved from https://www.daiichisankyo.com/ir/library/financial_results/pdf/fy2023_h1_presentation.pdf (Note: Specific fiscal year and reporting period should be verified with the latest official report.)

[5] Modi, S., Saura, C., Yamashita, T., Patel, M., Delcurtalare, T., Wu, W., ... & Cortes, J. (2020). Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Low, HER2-Mutated, and HER2-Amplified Metastatic Breast Cancer. Clinical Cancer Research, 26(19), 5270-5278.

[6] AstraZeneca PLC. (2023). Full Year Results 2023. Retrieved from https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-full-year-results-2023.html (Note: Specific sales projections and forecast figures should be verified with the latest official company reports.)